<!doctype html>
<html lang="en">
<meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1">
<title>Novo Nordisk Shares Rise as Obesity Trial Results Narrow Gap With Eli Lilly · Newsletter</title>
<style>
:root{--bg:#0f1221;--fg:#e8ecf3;--muted:#98a2b3;--link:#74b7ff;--card:#171b2f;--btn:#2563eb;--btnText:#fff;}
*{box-sizing:border-box} body{margin:0;font-family:ui-sans-serif,system-ui,-apple-system,Segoe UI,Roboto,Inter,Arial;background:var(--bg);color:var(--fg)}
.container{max-width:920px;margin:40px auto;padding:0 16px}
.header{display:flex;justify-content:space-between;align-items:center;gap:16px}
.brand{font-size:.95rem;font-weight:700;color:#8fb5ff}
.kicker{font-size:.85rem;color:var(--muted)}
.card{background:var(--card);border-radius:14px;padding:26px;margin-top:18px;box-shadow:0 6px 24px rgba(0,0,0,.35)}
h1{font-size:2rem;margin:.2rem 0 0}
.meta{font-size:.9rem;color:var(--muted);margin:.6rem 0 1rem}
ul{margin:12px 0 18px 22px;padding:0}
li{margin:.35rem 0;line-height:1.5}
a{color:var(--link);text-decoration:none}
a:hover{text-decoration:underline}
.btns{display:flex;gap:10px;margin-top:10px}
.btn{display:inline-block;background:transparent;border:1px solid #6b7280;color:#e5e7eb;padding:8px 12px;border-radius:8px;font-size:.9rem}
.btn.primary{background:var(--btn);border-color:var(--btn);color:var(--btnText)}
.footer{margin-top:26px;font-size:.8rem;color:var(--muted);text-align:center}
hr{border:0;border-top:1px solid #2a2f48;margin:18px 0}
</style>
<body>
  <div class="container">
    <div class="header">
      <div class="brand">Daily Finance Newsletter</div>
      <div class="kicker">5–7 key bullets per story</div>
    </div>

    <div class="card">
      <h1>Novo Nordisk Shares Rise as Obesity Trial Results Narrow Gap With Eli Lilly</h1>
      <div class="meta">2025-09-15 12:44:22+00:00 UTC</div>
      <ul>
        <li>Sep 15 - Novo Nordisk (NYSE:NVO) reported that a higher semaglutide dose helped patients lose more weight in two late-stage trials, and its Copenhagen-listed shares rose about 1.5%.</li>
        <li>The trials tested a 7.2 mg dose, three times the approved 2.4 mg, and measured weight change over 72 weeks.</li>
        <li>Eli Lilly (NYSE:LLY) posted stronger headline results with tirzepatide, achieving up to 22.5 percent weight loss at its top dose, keeping competition tight.Observers said the incremental gains for semaglutide matter, esp</li>
        <li>This article first appeared on GuruFocus.</li>
        <li>In the larger study, participants on 7.2 mg lost an average of 19 percent of body weight, compared with about 16 percent on 2.4 mg and 4 percent on placebo.</li>
        <li>Novo has faced setbacks in the U.S., including market share losses and a roughly 60 percent share decline over the past year as it trims its global workforce.</li>
        <li>The data may strengthen Novo&#x27;s case for higher-dose strategies if regulators and payers accept the approach.</li>
      </ul>
      <div class="btns">
        <a class="btn" href="https://finance.yahoo.com/news/novo-nordisk-shares-rise-obesity-124422607.html" target="_blank" rel="noopener nofollow">Original</a>
        <a class="btn primary" href="https://twitter.com/intent/tweet?text=Novo+Nordisk+Shares+Rise+as+Obesity+Trial+Results+Narrow+Gap+With+Eli+Lilly%0A%E2%80%A2+Sep+15+-+Novo+Nordisk+%28NYSE%3ANVO%29+reported+that+a+higher+semaglutide+dose+helped+patients+lose+more+weight+in+two+late-stage+trials%2C+and+its+Copenhagen-listed+shares+rose+about+%E2%80%A6%0Ahttps%3A%2F%2Ffinance.yahoo.com%2Fnews%2Fnovo-nordisk-shares-rise-obesity-124422607.html" target="_blank" rel="noopener">Share on X</a>
      </div>
      <div class="footer">© 2025 · Built from digest_5bullets.md</div>
    </div>
  </div>
</body>
</html>
